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Abstract
Introduction: This study is a part of the project on interferon gamma release assays performed in the group of untreated sarco-
idosis patients formerly BCG vaccinated. The aim of the study was to assess the rate of positive commercial interferon g release 
assays in sarcoidosis patients. We discussed the results in the context of hypothesis that M. tuberculosis antigens may play 
a role in the pathogenesis of sarcoidosis. 
Material and methods: 151 patients, mean age 38 ± 10.3, treatment naive, with newly diagnosed pulmonary sarcoidosis were 
enrolled into the study. All participants underwent QFT-GIT assay. A subgroup of 81 patients underwent also T-SPOT.TB assay.
Results: QFT-GIT was positive in 7/151. T-SPOT.TB was positive in 3/81. There were no indeterminate results in both IGRAs. 
There was no statistically significant relationship between IGRAs results and sarcoidosis parameters such as the radiologic stage, 
disease duration and the presence of Löfgren’s syndrome.
Conclusions: In sarcoidosis patients formerly BCG vaccinated, positive rate of IGRAs was 4.6% for QFT-GIT and 3.7% for T-SPOT.
TB. We did not find the influence of the selected parameters of sarcoidosis on IGRAs results.
Key words: sarcoidosis, interferon gamma release assays, latent tuberculosis infection
Pneumonol Alergol Pol 2015; 83: 126–134
Streszczenie
Wstęp: Prezentowana praca jest częścią projektu dotyczącego testów opartych na wydzielaniu interferonu gamma pod wpływem 
antygenów swoistych dla prątka gruźlicy przeprowadzonego na dużej grupie nieleczonych chorych na sarkoidozę w populacji 
powszechnie i wielokrotnie szczepionej przeciwko gruźlicy. Celem pracy była ocena wyników testów IGRA w tej grupie chorych. 
W pracy dyskutowany jest problem przydatności testów IGRA w wykrywaniu zakażenia prątkiem gruźlicy w kontekście współ-
cześnie prezentowanych poglądów dotyczących roli antygenów prątka gruźlicy w etiopatogenezie sarkoidozy. 
Materiał i metody: W badaniu uczestniczyło 151 chorych na sarkoidozę, w wieku 38 ± 10,3 roku, nigdy nieleczonych. Wszyscy 
uczestnicy badania mieli wykonany test QFT-GIT. Z grupy badanej utworzono podgrupę 81 chorych na sarkoidozę, którym wyko-
nano w tym samym czasie drugi test IGRA: T-SPOT.TB.
Wyniki: Dodatni wynik testu QFT-GIT stwierdzono u 7/151 badanych, a wynik testu T-SPOT-TB u 3/81 badanych. Nie stwier-
dzono wyników nieokreślonych. Nie stwierdzono statystycznie istotnej zależności pomiędzy wynikiem testu IGRA a wybranymi 
parametrami klinicznymi sarkoidozy.
Wnioski: U chorych na sarkoidozę szczepionych w przeszłości przeciwko gruźlicy szczepionką BCG odsetek dodatnich wyników IGRA wyno-
sił 4,6% dla QFT-GIT oraz 3,7% dla T-SPOT.TB. Nie wykazano wpływu wybranych parametrów klinicznych sarkoidozy na wynik testów IGRA.
Słowa kluczowe: sarkoidoza, testy oparte na wydzielaniu interferonu gamma, utajone zakażenie prątkiem gruźlicy
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Introduction
Sarcoidosis is a rare multiorgan granuloma-
tous disease, diagnosis of which often relies on 
properly conducted differential diagnosis of dis-
orders with similar clinical and histopathological 
features. On the top of a long list of granuloma-
tous diseases that need to be differentiated from 
sarcoidosis is tuberculosis. The necessity of ex-
clusion of tuberculosis as granulomatous disease 
of known origin is a sine qua non of diagnostic 
procedure in sarcoidosis, and it is included in 
a major pathologic differential diagnosis criteria 
for the disease [1, 2]. 
Exclusion of active tuberculosis during differ-
ential diagnosis is not equal to exclusion of latent 
tuberculosis infection (LTBI). In sarcoidosis pa-
tients, this aspect is particularly important in those 
who are going to be treated with immunosuppres-
sive drugs. The drugs used for treating sarcoidosis 
potentially increase the risk of LTBI progression to 
active disease. When prednisone at a dose of 15 mg 
(or other corticosteroid of equivalent dose) is used 
for at least 2−4 weeks, the risk of development of 
tuberculosis increases nearly 5-fold. In the case of 
TNF a antagonists, which are used in the treatment 
of refractory sarcoidosis, the risk of development 
of tuberculosis may grow even 17-fold [3].
The indirect evidence for the presence of 
infection with tubercle bacillus, without differen-
tiation between latent infection and active disease 
is a positive tuberculin skin test (TST). TST is 
not a perfect tool for detection of infection with 
M. tuberculosis (MTB) as it has its limitations. In 
Poland, where the population is obligatory BCG 
vaccinated since the 50s of the 20th century, TST 
may give false positive results. Whereas, in some 
sarcoidosis patients infected with MTB, TST may 
give false negative results due to dominating 
tuberculin anergy. 
At present, an alterative to TST are the tests 
based on the measurement of interferon gamma 
release by sensitized T lymphocytes in response 
to stimulation by antigens specific for M. tubercu-
losis [4]. These tests are: QuantiFERON–TB GOLD 
In-Tube (QFT-GIT) and T-SPOT.TB. In many stud-
ies, the advantage of interferon gamma release as-
says (IGRAs) over TST has been shown in respect 
of detection of MTB infection among the group of 
immunocompetent patients, particularly in BCG 
vaccinated populations [5, 6]. On the contrary 
in immunocompromised patients with dominant 
tuberculin anergy the value of IGRAs compared to 
TST are assessed equivocally, depending on the 
cause of immunosuppression [7−9].
In patients with sarcoidosis, the use of IGRAs 
in detection of LTBI may have a limited specif-
ity, as has been shown in the studies based on 
molecular and immunological methods, which 
concerned participation of tubercle bacillus an-
tigens in the ethiopathogenensis of sarcoidosis, 
with simultaneous lack of any evidence for the 
presence of an alive (metabolicaly active) micro-
organism in sarcoid granulomas [10−25].
The aim of the study was to assess the results 
of two commercial IGRAs and their value in de-
tection of MTB infection in the group of treatment 
naive patients with sarcoidosis in the population 
repeatedly vaccinated against TB.
Material and methods
The study group
The study group included 151 patients 
hospitalised at the First Department of Lung 
Diseases, National Institute of Tuberculosis 
and Lung Diseases (IGiChP, Instytut Gruźlicy 
i Chorób Płuc), Warsaw between October 2005 
and December 2011, in whom sarcoidosis at the 
stage I−IV was diagnosed. Sarcoidosis was diag-
nosed in accordance with the ATS/ERS/WASOG 
statement [1]. 
Active tuberculosis was excluded on the 
basis of the bacteriological investigation of the 
sputum, bronchial washing and biopsy specimens 
by Ziehl-Neelsen staining, culture on solid media 
(Löwenstein-Jensen medium) or by culture on 
liquid media (BACTEC — 460 TB system). 
The following patients were excluded from 
the study: 1) patients without confirmed diagno-
sis of the sarcoidosis due to lack of consent to 
further invasive diagnosis, in whom sarcoidosis 
was diagnosed basing solely on clinical image; 
2) patients who had sarcoidosis diagnosed outside 
the IGiChP and had no results of microbiologi-
cal examinations for exclusion of tuberculosis; 
3) patients treated with systemic or inhaled cor-
ticosteroids or other immunosuppressive drugs; 
4) patients with the diseases that may affect 
immunity; 5) patients who had TST performed 
during the previous 6 months; 6) pregnant wom-
en; 7) patients with mental disorders that limit 
conscious participation in the study, 8) patients 
who were under the age of 18.
All study participants were informed about 
the objective of the study and they gave their 
written informed consent to the participation 
therein. The study was approved by the Bioethical 
Committee of the National Institute of Tubercu-
losis and Lung Diseases.
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Methodology of the study
Venous blood samples were collected once 
from all 151 patients qualified for the study in 
order to perform at least one IGRA. All study 
participants underwent QFT-GIT assay. In the 
group of 81 patients the second IGRA, T-SPOT.
TB was performed simultaneously, without us-
ing any additional qualification criteria.
In addition, a questionnaire was complet-
ed with clinical characteristics concerning 
demographic data (age, sex), information on 
tuberculosis exposure (history concerning past 
tuberculosis or a possible contact with a per-
son with tuberculosis), and data regarding the 
course of the disease (stage of sarcoidosis, the 
presence of Löfgren’s  syndrome, duration of 
the disease). 
QFT-GIT was performed by qualified staff of 
the Department of Laboratory Diagnostics (ZDL, 
Zakład Diagnostyki Laboratoryjnej), IGiChP 
using a commercial set produced by Cellestis 
Limited, Carnegie, Victoria, Australia, in accor-
dance with the manufacturer’s guidelines [26]. 
The results were divided in three categories: 
negative, positive and indeterminate. QFT-GIT 
≥ 0.35 IU/ml was considered as a positive result.
T-SPOT.TB assay was performed by a qu-
alified laboratory diagnostic technician of the 
Department of Microbiology, IGiChP using 
a  commercial set produced by Immunotec 
Limited, Abingdon, Great Britain, precisely in 
accordance with the manufacturer’s guidelines 
[27]. The results of T-SPOT.TB were grouped 
in the three categories: negative, positive and 
indeterminate. 6 spots or more were considered 
as a positive result.
Statistical analysis
The results of the study were analysed 
using the commercial programme for statistical 
analysis STATISTICA, version 9 produced by 
StatSoft Poland.
Descriptive results were presented, in the 
case of quantitative data, as means and standard 
deviations, and in the case of qualitative data 
— as numbers and percentages. 
Depending on the selected demographic 
and clinical parameters, the results of IGRA 
were analysed as binary values. For qualitative 
and binary variables, depending on expected 
numbers, chi-square test or its variations (chi
-square, V-square) were used. For the remaining 
variables the Mann-Withney test was used. 
P < 0.05 was assumed as statistically significant.
Results
Characteristic of the study group
The study group included 151 patients with 
sarcoidosis (97 men and 54 women). The mean 
age in the study group was 38 ± 10.3 years. Sar-
coidosis was diagnosed in 32 cases on the basis 
of the presence of Löfgren’s  syndrome, in the 
remaining 119 patients it was confirmed histo-
pathologically. 1 sarcoidosis patient, in whom 
histopathological confirmation was obtained, had 
also Löfgren’s syndrome. The roentgenographic 
stages of thoracic changes were as follows: stage 
I was diagnosed in 71 patients, stage II — in 72 
patients, stage III — in 4 patients, and stage IV 
— in 4 patients. The time from the onset of symp-
toms to diagnosis of the disease ranged from 0.25 
to 60 months. All patients had a negative result 
of AFB smear and a negative results of sputum, 
bronchial washings or biopsy specimens cultures 
for tuberculosis. 16 patients reported a history of 
contact with a person with tuberculosis. In the 
remaining 135 cases, exposure to tuberculosis 
was not found. None of the subjects from the 
study group suffered from tuberculosis in the 
past. Observation time of patients amounted on 
average 14.8 months. During this time no single 
case of tuberculosis occured among the study 
participants. A detailed clinical characteristic of 
the study group is presented in Table 1.
The results of QFT-GIT
The range of the results of QFT-GIT in the 
study group was from 0 IU/ml to 3.217 IU/ml, 
on average 0.09 ± 0.35 IU/ml. Positive results of 
QFT-GIT made up 4.6%, whereas negative 95.4% 
of all results (Fig. 1). There were no indeterminate 
results.
The results of QFT-GIT were also analysed 
according to the selected demographic and clini-
cal parameters (Table 2).
The group with a positive result of QFT-GIT 
was distinguished by older age, compared to the 
group with a negative result (44.4 ± 15.2 vs 37.7 
± 9.9). However, the difference was not statisti-
cally significant (p = 0.1979; Mann-Whitney test).
No statistically significant correlation was 
found between the result of QFT-GIT and sex 
(p = 0.4209, chi-square test with Yates’ correction).
When the results of QFT-GIT were analysed 
depending on the stage of sarcoidosis, a positi-
ve result of QFT-GIT was found in 5/71 (7%) 
sarcoidosis patients at the stage I, and in 2/71 
(2.8%) patients at the stage II. All patients with 
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Table 1. Baseline characteristics of study group
n = 151 (%)
Age (yrs) range
 mean ± standard deviation
 median
22–69 
38 ± 10.3
35
Age group (yrs)
 ≤ 29 
 30–39
 40–49
 50–59
 ≥ 60
30 (19.9)
69 (45.7)
25 (16.5)
21 (13.9)
6 (4)
Gender:
 male
 female
97 (64.2)
54 (35.8)
Stage of sarcoidosis:
 I
 II
 III
 IV
71 (47.0)
72 (47.8)
4 (2.6)
4 (2.6)
Löfgren’s syndrom 33 (21.9)
Duration of sarcoidosis 
(month):
 < 1 
 1–3
 4–6
 7–12
 > 12
3 (2.0)
71 (47.0)
43 (28.5)
22 (14.6)
12 (7.9)
TB exposure
 yes
 no
16 (10.6)
135 (89.4)
Figure 1. QFT-GIT results
Table 2. Relationship between QFT-GIT results and demo-
graphic and clinical data in study group
p
Age 0.1979
Gender 0.4209
Stage of sarcoidosis 0.2270
Duration of sarcoidosis 0.3635
Presence of Löfgren’s syndrom 0.5592
TB exposure 0.6124
Figure 2. T-SPOT.TB results
lation between duration of sarcoidosis and the 
result of QFT-GIT was not found (p = 0.5592, 
Mann-Whitney test). 
No correlation between the QFT-GIT results 
and exposure to tuberculosis was found (p = 
0.6124; chi-square test with Yates’ correction).
The results of T-SPOT.TB assay
T-SPOT.TB results were obtained in a subgro-
up of 81 patients with sarcoidosis. 3 (3.7%) po-
sitive results of the T-SPOT.TB assay were found. 
The remaining (96.3%) results were negative. No 
indeterminate results were observed. Qualitative 
distribution of results is presented in Figure 2.
The age of sarcoidosis patients who tested 
negatively for T-SPOT.TB amounted on average to 
38.3 ± 10.5 years, and of those who tested positi-
vely — to 37 ± 2.6. There were 2 men and 1 woman 
among the patients who tested positively. 1 out 
of 3 patients had a positive result of both IGRAs. 
A detailed clinical characteristic with a positive 
result of T-SPOT.TB was presented in Table 3.
No correlation between T-SPOT.TB assay 
result and age (p = 0.6526; Mann-Whitney test), 
or sex was found (p = 0.5875; chi-square test with 
Yates’ correction). 
sarcoidosis at the stage III and IV tested negati-
vely for QFT. However, correlation between the 
result of QFT-GIT and the stage of sarcoidosis was 
not statistically significant (p = 0.2270, Mann- 
-Whitney test).
No statistically significant correlation was 
found between the result of QFT-GIT and the 
presence of Löfgren’s  syndrome (p = 0.3635, 
chi-square test with Yates’ correction). 
The results of QFT-GIT were also analysed 
depending on the duration of the disease. Corre-
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Table 3. Patients characteristics with positive T-SPOT.TB result
Patient no. 1 Patient no. 2 Patient no. 3
Age (year) 39 34 38
Gender Male Female Male
Stage of sarcoidosis IV I I
Presence of Löfgren’s syndrom No Yes No
Duration of sarcoidosis (months) 60 6 2
TBC exposure No No No
TST result 10 mm 12 mm 6 mm
QFT result:
   quantitative 
   qualitative
0.22 IU/ml
negative
0 IU/ml
negative
1.32 IU/ml
positive
Table 4.  Relationship between T-SPOT.TB results and 
demographic and clinical data in study group
p
Age 0.6526
Gender 0.5875
Stage of sarcoidosis 0.9005
Duration of sarcoidosis 0.2252
Presence of Löfgren’s syndrom 0.9329
TB exposure 0.7550
T-SPOT.TB results were not dependent on the 
stage of sarcoidosis (p = 0.9005, Mann-Whitney 
test). The correlation between the test result and 
the presence of Löfgren’s syndrome was not found 
either (p = 0.9329, chi-square test with Yates’ 
correction). Duration of sarcoidosis did not have 
statisitically significant impact on the test result 
(p = 0.2252; Mann-Whitney test). No correlation 
was found between the test result and exposure 
to tuberculosis (p = 0.7550; chi-square test with 
Yates’ correction). 
The analysis of the influence of selected 
demographic and clinical parameters on the 
T-SPOT.TB assay results is presented in Table 4.
Discussion
For more than 10 years now, IGRAs are used 
in various countries to identify infection with 
tubercle bacillus. It is the only officially registe-
red indication for the use of these assays. During 
this time thousands of studies were published 
concerning the application of IGRAs, both in 
immunocompetent as well as immunocompro-
mised subjects. There are barely a  few studies 
that concern sarcoidosis patients. Although 
there are many reasons for interest in this group 
of patients regarding the possibility of IGRAs 
appliacance, starting from LTBI identification, 
through differentiation between sarcoidosis and 
tuberculosis, and even searching for evidence of 
common ethiopathogenesis of the two diseases. 
In 2008, Inui et al. published the results of 
the first study with the use of commercial IGRA 
in patients with sarcoidosis [28]. Positive result of 
QFT was found in 3.3% of the study participants. 
Similar results were obtained in our own material. 
In the study group, positive result of QFT-GIT was 
found in 4.6% of sarcoidosis patients. Whereas 
Gupta et al. found positive result of QFT-GIT in 
as many as 34.2% patients with sarcoidosis [29]. 
On the other hand, Milman et al. did not find any 
positive result of QFT-GIT in the examined group 
of sarcoidosis patients [30].
Contrary to QFT, there has been only one 
study published in English that used the second 
commercial IGRA — T-SPOT.TB in sarcoidosis 
patients so far. German authors (Hörster et al.) fo-
und positive result of T-SPOT.TB in 5/17 (29.4%) 
of sarcoidosis patients [31]. In our study which 
was conducted in a significantly greater group, 
positive result of T-SPOT.TB was found merely 
in 3/81 (3.7%) sarcoidosis patients. 
Apart from determinate (positive, negative) 
IGRAs results, there are also indeterminate results 
that are the effect of incorrect reaction in negative 
control or/and positive control with mitogen. The 
data of the in vitro reactivity of peripheral blood 
lymphocytes to phytohemagglutinin (PHA) in 
sarcoidosis are contradictory. According to them, 
too high number of indeterminate results may 
restrict the use of IGRA in this group of patients. 
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Earlier mentioned studies did not confirm these 
doubts. Solely in the study by Milman et al., in 
which sarcoidosis patients qualified for biological 
therapy were examined, indeterminate results 
of T-SPOT.TB were found. They constituted 7% 
of all results and concerned the patients on im-
munosuppressants, and in 1 case — the person 
infected with HIV [30]. The outcome has not been 
high. Helwig et al. found 28.9% of indeterminate 
results of QFT in the candidates for anti-TNFa 
treatment due to inflammatory bowel disease [32]. 
Cattamanchi et al. in their meta-analysis of the 
studies concerning HIV infected patients found 
indeterminate results of QFT-GIT in 2−11% of the 
subjects, and of T.SPOT.TB in 0−13% [8]. Diel et al., 
who analysed 116 studies, showed that the 
proportion of indeterminate results fluctuated 
between 0−40.96% (on average 2.14% for all 
studies and 4.42% in the subgroup of immuno-
compromised patients) for QFT, and 0 — 33.73% 
(on average 3.8% for all studies and 6.12% in the 
subgroup of immunocompromised patients) for 
T-SPOT.TB [33]. Whereas in the meta-analysis 
conducted by Sester et al, the proportion of in-
determinate results of QFT amounted to 7%, and 
that of T.SPOT.TB — to 3.4% [34]. In our own 
material, we did not find indeterminate results 
in any case. As we mentioned above, the patients 
treated with immunossuppresive drugs or with 
other immunodificiency conditions were not 
included into our study. In 101/151 QFT-GIT and 
81/81 T-SPOT.TB assays, the tests was performed 
with a positive control. INFg release measured by 
QFT-GIT after stimulation with mitogen was in 
the normal range (0.86 IU/mL to > 10 IU/mL). In 
T-SPOT.TB, in all study participants (81/81), spots 
count in positive control exceeded 20.
However, from practical point of view, only 
determinate results are crucial for diagnosis. 
According to the intention of IGRAs’ inventors, 
interpretation of the test result should be restric-
ted to diagnosis of latent infection with MTB. 
However, in sarcoidosis patients, it is not so clear 
due to numerous reasons. Positive IGRAs should 
be treated as indirect proof of MTB infection, 
which confirms the presence of immunological 
response of the patient to mycobacterial antigens 
but which is not the evidence of the presence of 
alive microorganisms in his/her body. 
Etiological factor of sarcoidosis remains still 
unknown. Due to clinical and histopathological 
similarity between sarcoidosis and tuberculosis, 
the majority of present studies focus on searching 
for the proof of the hypothesis that the myco-
bacteria are the etiological factor of sarcoidosis. 
In recent years, many studies appeared that 
identified mycobacterial antigens in sarcoidosis 
patients or T-cell and B-cell response to these an-
tigens. Various mycobacterial antigens have been 
studied: early secreted antigenic target (ESAT-6), 
catalase-peroxidase (katG), superoxide dismutase 
(sodA), mycolyl transferase (Ag85A) and heat 
shock protein (hsp). ESAT-6 is the same antigen 
that is used in commercial IGRAs to stimulate T 
lymphocytes. 
Using the ELISPOT method, Drake et al., 
detected in 8/26 (30.7%) sarcoidosis patients INF 
g production from peripheral blood mononuclear 
cells (PBMC) after stimulation with ESAT-6 [16]. 
In the same year positive results of the immune 
response to 3 mycobacterial antigens, including 
ESAT-6, were published by Carlisle et al. They 
identified PBMC response to this antigen in 12/30 
(40%) of sarcoidosis patients [17]. In both stu-
dies statistically significant difference was found 
between the study group and the control group 
with negative TST. Lymphocyte reactivity in 
bronchoalveolar lavage fluid (BALF) to various 
mycobacterial antigens have been also studied. 
Oswald-Richter et al. detected CD4+ T-cell response 
to ESAT-6 or katG in BALF in 73% of sarcoidosis 
patients [18]. The same author in his subsequent 
paper reported that ESAT-6 induces the most frequ-
ent stimulation of Th1 immune response in these 
patients, as compared to katG, Ag85A, sodA and 
Hsp70 [19]. Recently, Oswald-Richter et al., using 
matrix-assisted laser desorption ionization imaging 
mass spectrometry localized signal consistent with 
antigen ESAT-6 in sarcoidosis granulomas [20]. 
Considering the outcome of these studies, 
one could expect high proportion of positive 
IGRA results in sarcoidosis patients. But what 
we found in the study material is not the case. 
Then how the differences can be explained? By 
different sensitivity due to various methodology 
of the studies? ESAT-6 antigen is a 6 kDa mole-
cule. In experimental studies various amino acid 
sequences of peptide fragments of the ESAT-6 
antigen are used. Although Drake et al. used 17 
ESAT-6 peptides of various amino acid sequen-
ce, only one of them, NNALQNLARTISEAG was 
recognised by blood lymphocytes of sarcoidosis 
patients [16], whereas Carlisle et al. observed Th1 
response to multiple peptides within ESAT-6 [17]. 
In commercial tests, ESAT-6 antigen provided by 
the manufacturer is used. But the reasons may be 
different, therefore, the study that would compare 
the two methods is needed. 
Carlisle et al. put forward a hypothesis that 
lack of response to mycobacterial antigens in 
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some sarcoidosis patients may suggest that they 
had been wrongly diagnosed [17]. In our study 
material, sarcoidosis was diagnosed in accordan-
ce with the applicable quidelines [1].
According to another hypothesis, identi-
fication of immune response to mycobacterial 
antigens depends on whether the disease is in 
active phase or in remission. This theory has 
been confirmed in the study by Chen et al., who 
found statistically significant difference (p = 
0.027) in response of T lymphocytes to katG 
antigen between the two groups [23]. In our stu-
dy, the impact of chosen clinical parameters of 
sarcoidosis on IGRAs results was analysed. No 
statistically significant correlation was found 
between the results of QFT-GIT and T-SPOT.TB 
and sarcoidosis stage, features of acute course 
(Löfgren’s syndrome) and duration of the disease. 
Oswald-Richter et al. have proven that the 
presence of response to mycobacterial antigen is 
related to the occurrence of certain allele (HLA, 
human leukocyte antigen). In their research 
they found correlation between the presence of 
response to ESAT-6 and katG antigens and the 
occurrence of DRB1* 1101 HLA allele in sarco-
idosis patients [35].
The results of commercial IGRAs in sarco-
idosis patients are different in various studies. 
The majority of studies have shown that the 
prevalence of positive results of IGRAs in sarco-
idosis patients reflects different epidemiological 
situation of tuberculosis in the countries where the 
studies were conducted. The study by Gupta et al. 
was carried out in the country of high incidence 
of tuberculosis — 178/100 000 (India), whereas 
the research by Milman et al. was conducted in 
Denmark, where incidence of tuberculosis is low 
(7.4/100 000) [36]. The exception is a German stu-
dy which results have not correlated with a low 
incidence of tuberculosis in this country (5.6/ 
/100 000). Hörster et al. have specified that a lar-
ge group of the study participants was from the 
countries of high incidence of tuberculosis [31]. 
Moreover, it cannot be excluded that IGRAs 
do not detect all persons infected with tubercle 
bacilli among sarcoidosis patients. It would be 
supported by the outcome obtained in our mate-
rial, i.e. substantially lower percentage of positive 
results of IGRAs, compared to results obtained in 
a group of healthy volunteers who were exami-
ned by Kuś et al. [37]. However, this difference 
has a logical explanation. The study groups were 
different with respect to age, which influences the 
proportion of positive IGRAs results. Furthermore, 
the group examined by the author was exposed to 
infection with tubercle bacillus to a slight degree, 
which is reflected in small proportion of subjects 
reporting in history of tuberculosis contacts. The 
studies by other authors have shown that there is 
a significant correlation between positive result 
of IGRAs and the degree of tuberculosis exposure 
[38]. As in our study conducted among sarcoido-
sis patients, correlation between IGRAs results 
and exposure to tuberculosis was not found, it 
may be assumed that exposure to infection with 
MTB was minimal. The percentage of positive 
results in sarcoidosis patients in the study by 
Gupta et al. was also lower than in the healthy 
population [29]. Similar disproportion of IGRAs 
results can be found in the population with re-
tained skin sensitivity to tuberculin. Kang et al. 
have found in the group of healthy individuals 
with no risk factors of tuberculosis, positive re-
sults in merely 4% of the subjects, whereas the 
proportion of people infected with tuberculosis 
in the general population was estimated by them 
at approximately 33% [39]. Lack of indeterminate 
results of IGRAs in sarcoidosis patients, particu-
larly those that are caused by impaired peripheral 
blood lymphocytes reactivity after stimulation 
with mitogen (the so called positive control) im-
plies that the occurrence of false negative results 
in the study group is little probable.
Of note is the precision with which IGRA re-
sult predicts the risk of occurrence of progression 
from LTBI to active tuberculosis. The follow-up 
observation of our study material, showed that 
there was no occurrence of tuberculosis among 
sarcoidosis patients who tested negatively for 
QFT-GIT or T-SPOT.TB. Milman et al., when se-
lected sarcoidosis patients for TNF-a antagonists 
treatment have proved high negative predictive 
value of Quantiferon test for progression to active 
tuberculosis [30]. In the group that they exami-
ned, 2 persons with negative QFT result received 
treatment with etanercept and adalimumab. 
None of them came down with tuberculosis at 
follow-up. It is in accordance with the outcome 
of meta-analysis by Diel et al., in which negative 
predictive value for progression to active tuber-
culosis in the countries with low tuberculosis 
incidence was high and amounted to 99.8% for 
QFT-GIT test and 97.8% for T-SPOT.TB [40].
Some authors have taken the controversial 
position that IGRAs may be used for differential 
diagnosis of sarcoidosis and tuberculosis [41]. 
They believe that if initial condition of tuber-
culosis is LTBI, the assessment of the presence of 
infection enables rapid exclusion of tuberculosis 
in the patient with suspected sarcoidosis. This 
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point of view is supported by lack of rapid and 
sensitive tests for differentiation between the two 
diseases. But this position has many weak points. 
It is known that only very few persons out of those 
infected with MTB come down with tuberculo-
sis. According to the meta-analysis conducted 
by Diel et al., negative predictive value of IGRAs 
evaluated in patients with bacteriologically con-
firmed tuberculosis ranged between 70−100%, 
with a pooled value of 94% for T-SPOT.TB and 
88% for QFT-GIT [40]. In the meta-analysis of 
the same author published one year earlier, sen-
sitivity of QFT-GIT and T-SPOT.TB in patients 
with bacteriologically confirmed tuberculosis 
was 81% and 87.5%, respectively [33]. In another 
meta-analysis (Sester et al.) sensitivity of IGRAs 
in tuberculosis patients was 80−81% depending 
on the test. [42]. On the other hand, specificity 
of IGRAs in these patients was 79% and 59%, for 
QFT-GIT and T-SPOT.TB respectively, and was 
definitely lower than specificity evaluated in the 
earlier meta-analysis by Diel et al. [33] (99% and 
86%). In practice, it means that sensitivity of 
IGRAs is insufficient to definitely exclude tuber-
culosis basing on their negative result. Whereas 
specificity of IGRAs is unsatisfactory to diagnose 
tuberculosis, as the positive result does not diffe-
rentiate the active disease from LTBI. 
Conclusions
In sarcoidosis patients formerly BCG vacci-
nated against tuberculosis, the rate of IGRAs was 
4.6% for QFT-GIT and 3.7% for T-SPOT.TB. The 
influence of the selected clinical parameters of sar-
coidosis on the results of IGRAs has not been found. 
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